Drugs / NMS-1116354
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01092052 | Jan 2010 → Jul 2012 | — | Nerviano Medical Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT01016327 | Apr 2009 → Dec 2011 | cancer | Nerviano Medical Sciences | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMS-1116354 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01016327 ↗ |
| Action | Inhibit | “a CDC7 kinase inhibitor” NCT01016327 ↗ |
| Route | Oral | “Oral daily administration for 7 consecutive days every 14 days” NCT01016327 ↗ |
| Target | CDC7 | “a CDC7 kinase inhibitor” NCT01016327 ↗ |